Drug intelligence / Profile preview

PRT-004

Development stage: Unknown
Lead developer: Protai

Overview

PRT-004 is a discovery-stage drug candidate being developed by Protai for the treatment of immunology and inflammation (I&I) disorders. The program is part of Protai's pipeline, which utilizes their AIMS™ platform to identify novel drug targets and therapeutic candidates. The AIMS™ platform integrates proteomics and machine learning to map protein interactions and identify disease-driving proteins. As of early 2024, specific details regarding the biological target, molecular modality, and mechanism of action for PRT-004 have not been publicly disclosed by the company.

Beyond the preview

Go deeper on PRT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-004.

Explore the full profile